Mnemo Therapeutics

[Mnemo Therapeutics @MnemoTx]

Exploiting the Dark Proteome : at @MnemoTx we are developing #immunotherapies that target ‘dark proteome-derived antigens’ produced by #cancer cells and presented by MHC molecules, thus addressing unmet medical needs.

Find out more ➡️https://t.co/2TgAnqqStA

[Mnemo Therapeutics @MnemoTx]

See the latest contribution of @MnemoTx team on developing a robust, tumor-specific target discovery platform for next-generation immunotherapies in the latest edition of @MabDesign's Immunowatch :

https://t.co/LA7YZyW9P9

#Immunotherapy #darkgenome #biotech #health

[Mnemo Therapeutics @MnemoTx]

We hope to see you at CAR-TCR Europe! Don’t miss presentations by Mnemo's Michael Saitakis. We look forward to connecting with others in #biotech, academia and #pharmaceuticals as we work to develop actionable therapeutics. Learn more at https://t.co/HRClARDGik

[Mnemo Therapeutics @MnemoTx]

We had a wonderful time at #HYBRIDAYS 2024! Thank you to everyone who came to hear from Mnemo's Senior Director of Strategic R&D Operations & Alliances George Lourenço and Associate Director Immunotherapy Michael Saitakis.
Photos courtesy of @NathalieOundjian

[Mnemo Therapeutics @MnemoTx]

Congratulations to those selected to share their work at HYBRIDAYS 2024, an international forum that sparks collaboration between leaders in academia, biotechnology, and pharma. George Lourenço and Michael Saitakis look forward to presenting. Register: https://t.co/6msMYH6viI

[Mnemo Therapeutics @MnemoTx]

Two studies by Mnemo scientists and collaborators, aimed at improving #CART cell efficacy and persistence, were published in the January issue of Cancer Discovery (by @AACR) and featured on the cover. Learn about the cover art and read the articles here: https://t.co/ChorUrucT3

[Mnemo Therapeutics @MnemoTx]

Mnemo Associate Directors Theodoros Giavridis and Michael Saitakis will present on e-antigens and #CART cell persistence at the #KeystoneSymposia on #Molecular & #Cellular Biology's Emerging #CellularTherapies Conference January 22-25. For more info: https://t.co/HpR4vg8aWG

[Mnemo Therapeutics @MnemoTx]

Mnemo team members look forward to presenting at the Dark Genome Symposium and connecting with professionals in biotech, academia, and pharmaceuticals. Together, we can illuminate the long-mysterious #darkgenome and develop actionable therapeutics.

[Mnemo Therapeutics @MnemoTx]

Our new study in collaboration with @institut_curie shows that ablating SUV39H1 enhances T cell memory and persistence, while reducing T cell exhaustion and protecting against tumor relapses in mouse models. Learn more: https://t.co/6TU7jHOIoT

[Mnemo Therapeutics @MnemoTx]

Mnemo's Michael Saitakis is attending the VII Siena NIBIT Foundation Think Tank this week, where he will discuss epigenetic reprogramming of CAR T cells in solid tumors. This video explains why Mnemo inactivates SUV39H1 to promote T cell persistence and defeat solid tumors.

[Mnemo Therapeutics @MnemoTx]

Congratulations to Mnemo Scientific Co-Founder Michel Sadelain @MSKCancerCenter, who has earned the Breakthrough Prize, the world's largest scientific prize, for his significant contributions in immunology, genetic engineering, and cell therapy. https://t.co/si4PjYmADx

[Mnemo Therapeutics @MnemoTx]

This year's DC BIOL event, sponsored by Mnemo and organized by @institut_curie + @CIML_Immunology, united international participants for three days of learning. Team Mnemo presented three posters and participated in two discussions. Thank you to the organizers and participants!

[Mnemo Therapeutics @MnemoTx]

At the 6th Annual DCBiol Course on Immunity and Cancer Immunotherapy, Mnemo will present 3 posters and participate in 2 discussions about novel sources and approaches for tumor-specific targets. Sponsored by Mnemo, organized by
@institut_curie @CIML_Immunology #immunotherapies

[Mnemo Therapeutics @MnemoTx]

Join us in congratulating Mnemo Scientific Co-Founders & Scientific Advisors Isabelle Rivière, PhD, and Justin Eyquem, PhD, on their recent recognition as American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting Award recipients! Read more: https://t.co/CIdLtQ9f9s

[Mnemo Therapeutics @MnemoTx]

BioEquity Europe offers a valuable opportunity to connect with biotech CEOs and investors committed to forging meaningful partnerships and advancing the industry. We hope to see you in Dublin! #BioEquity

[Mnemo Therapeutics @MnemoTx]

Join us in congratulating Isabelle Rivière, PhD, Mnemo Scientific Co-Founder and Scientific Advisor for being recognized as an American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting Award recipient! Read more: https://t.co/CIdLtQ9f9s…

[Mnemo Therapeutics @MnemoTx]

Join us in congratulating Justin Eyquem, PhD, Mnemo Scientific Co-Founder & Scientific Advisor for being recognized as an American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting Award recipient! Read more: https://t.co/CIdLtQ9f9s

[Mnemo Therapeutics @MnemoTx]

We're front-page news! This month's @SciImmunology cover depicts tumor-infiltrating lymphocytes seeking out TE-exon splicing junctions, a new class of cancer-specific targets. Articles: https://t.co/w2Gj54atxn and https://t.co/6sWwiuDAFa Art: Alexis Finkbeiner.

[Mnemo Therapeutics @MnemoTx]

We are pleased to share two studies out today in @SciImmunology. Scientists identified a class of novel, recurrent, cancer-specific targets with potential implications for developing more effective, less toxic immunotherapies. More: https://t.co/w2Gj54atxn https://t.co/6sWwiuDAFa

[Mnemo Therapeutics @MnemoTx]

Several members of the Mnemo leadership team are attending this year’s #JPMorgan Healthcare Conference. We’re looking forward to connecting with fellow global industry leaders and investors, and hope to see you there #JPM23.